17 results
8-K
EX-99.1
CRBU
Caribou Biosciences Inc
8 Jan 24
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
8:00am
, leading the company’s people strategy.
Expanded Caribou’s SAB with a renowned lymphoma expert and two leading multiple myeloma experts:
◦Stephen Schuster
424B5
CRBU
Caribou Biosciences Inc
14 Jul 23
Prospectus supplement for primary offering
5:31pm
supplement is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters.
Notice to Prospective
424B5
CRBU
Caribou Biosciences Inc
13 Jul 23
Prospectus supplement for primary offering
4:56pm
expert advice on those matters.
Notice to Prospective Investors in Hong Kong
The securities have not been offered or sold and will not be offered
DEF 14A
y33iy4l8l919b1xks
11 Aug 22
Definitive proxy
4:04pm
10-K
3sg90fu 34xsw6
21 Mar 22
Annual report
4:19pm
8-K
EX-10.1
nb8iswzo
19 Jan 22
Entry into a Material Definitive Agreement
4:19pm
424B4
lbr837t8pkujjfpjdqj
23 Jul 21
Prospectus supplement with pricing info
4:24pm
S-1/A
z3vspr0pm9
19 Jul 21
IPO registration (amended)
6:09am
S-1
am0 o0kyubmg
1 Jul 21
IPO registration
4:05pm
S-1
EX-10.26
q781aa1
1 Jul 21
IPO registration
4:05pm
S-1
EX-10.50
yhjfdfwhgmbeyyt595
1 Jul 21
IPO registration
4:05pm
DRS/A
oo574d bswhhsvups2
11 Jun 21
Draft registration statement (amended)
12:00am
DRS
mmgf1y2mmjf1pvvk
7 May 21
Draft registration statement
12:00am
DRS
EX-10.23
5ym0bggbh
7 May 21
Draft registration statement
12:00am
- Prev
- 1
- Next